Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Items 801–900 of 1,001
Secondary metabolites from Penicillium sp. HS-11, a fungal endophyte of Huperzia serrata
Ying, Y., Lei, P., Xu, Y., Lin, Y., Yang, N., Han, Y., Zhang, Z., Shan, W., Rao, G., & Wang, J. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.105943 · Cited by 5
The Microbiota in Cancer: A Secondary Player or a Protagonist?
García, A. M. G., Lopez-Munoz, F. J., & García‐Rico, E. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080463 · Cited by 6
Zhu, Y., Liu, Q., Alffenaar, J. C., Wang, S., Cao, J., Dong, S., Zhou, X., Li, X.-X., Li, X., Xiong, H., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3687 · Cited by 5
Yang, J., Li, S., Liu, Y., Li, R., & Long, L. (2021) · Applied and Environmental Microbiology · doi:10.1128/aem.02226-21 · Cited by 5
Tao, G., Chityala, P. K., Li, L., Lin, Z., & Ghose, R. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109946 · Cited by 5
Kerins, A., Koszyczarek, M. M., Smith, C. A., Butler, P. J., Riley, R. J., Madgula, V. L. M., Naik, N., Redinbo, M. R., & Wilson, I. D. (2022) · Xenobiotica · doi:10.1080/00498254.2022.2128468 · Cited by 5
Self-citationOverview of structure-function relationships of glucuronidases
Mohapatra, S. B., & Manoj, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91805-3.00015-0 · Cited by 7
Kolodnitsky, A. S., Ионов, Н. С., Rudik, A. V., Lagunin, A. A., Filimonov, D. A., & Poroikov, V. (2023) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2023.2214375 · Cited by 5
Lu, C., Hou, X., Zhu, G., Huang, J., Guo, Z.-B., Zhang, Y., Sun, J.-M., Ma, L.-J., Zhang, S., Hou, J., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131150 · Cited by 5
Marsh, D. T., & Smid, S. D. (2024) · Toxicology in Vitro · doi:10.1016/j.tiv.2024.105888 · Cited by 6
Barking up the wrong genome - we are not alone
Li‐Wan‐Po, A., & Farndon, P. A. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01240.x · Cited by 6
What changes in inflammatory bowel disease management can be implemented today?
Louis, E. J., Baumgart, D. C., Ghosh, S. K., Gomollón, F., Hanauer, S. B., Hart, A. L., & Irving, P. M. (2012) · Journal of Crohn s and Colitis · doi:10.1016/s1873-9946(12)60506-6 · Cited by 5
Monitoring glycosidase activity for clustered sugar substrates, a study on β-glucuronidase
Brissonnet, Y., Compain, G., Renoux, B., Krammer, E., Daligault, F., Deniaud, D., Papot, S., & Gouin, S. G. (2019) · RSC Advances · doi:10.1039/c9ra08847d · Cited by 5
Gut Microbiome: The Third Musketeer in the Cancer-Immune System Cross-Talk
Sharma, P., Jain, T., Sethi, V., Iyer, S., & Dudeja, V. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000057 · Cited by 7
Yu, W., Liu, X., Cai, D., Zheng, J., Lao, B., Huang, M., & Zhong, G. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2346 · Cited by 5
Li, J., Wang, Y., Hao, Y., Huo, X., Sun, C., Zhao, X.-X., Wang, J., Zhang, J., Ning, J., Tian, X., et al. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e21394 · Cited by 5
Linking interpersonal differences in gut microbiota composition and drug biotransformation activityPreprint
Mastrorilli, E., Herd, P., Rey, F. E., Goodman, A. L., & Zimmermann, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.21.700809 · Cited by 5
Uoti, A., Neulasalmi, O., Hiippala, K., Oksanen, T., Arkkila, P., Puustinen, L., Satokari, R. M., & Sjöstedt, N. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100205 · Cited by 4
Phenotypic high-throughput screening identifies modulators of gut microbial choline metabolism
Woo, A. Y. M., Sandoval-Espínola, W. J., Bollenbach, M., Wong, A., Sakanaka, M., Zhang, Q., Nieto, V., Rey, F. E., & Balskus, E. P. (2026) · mBio · doi:10.1128/mbio.01172-25 · Cited by 4
Böhm, D. T. M. M., Guchelaar, H., Smidt, M. L., & Deenen, M. J. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11024-8 · Cited by 4
Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility
Lagomarsino, V. N., Robinson, A. F., Mitchell, P. E., Jiang, M., Hutchinson, L., Sekela, J. J., Caron, P., Gehris, M. K., Navas, K. I., Duarte-Silva, M., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02321-0 · Cited by 4
Self-citationRecent advances and clinical relevance of microbiome dynamics in health and disease
Gavanji, S., Suhail, M., Bencúrová, E., Dandekar, T., & Othman, E. M. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2679197 · Cited by 4
Diversity oriented total synthesis (DOTS) of pyridoquinazolinone alkaloids and their analogues
Rasapalli, S., Huang, Y., Sammeta, V. R., Alshehry, R., Anver, F., Golen, J. A., Krishnamoorthy, S., & Chavan, S. P. (2024) · Tetrahedron Chem · doi:10.1016/j.tchem.2024.100062 · Cited by 4
Kerins, A., Butler, P. J., Riley, R. J., Koszyczarek, M. M., Smith, C. A., Cruickshank, F. L., Madgula, V. L. M., Naik, N., Redinbo, M. R., & Wilson, I. D. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2357765 · Cited by 4
Self-citationZhang, Y., Qiu, R., Zhang, Z., Almutairi, M. H., Nawaz, S., & Dong, S. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1446924 · Cited by 4
Tai, Y.-H., Kao, C., Zhang, Y., Chiou, Y., Chiu, H.-H., Thuy, T. T. D., & Liao, H. (2024) · Talanta · doi:10.1016/j.talanta.2024.127094 · Cited by 4
Turco, L., Monica, R. D., Giordano, P., Cuomo, M., Biazzo, M., Mateu, B., Liello, R. D., Daniele, B., Normanno, N., Luca, A. D., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1458990 · Cited by 4
A uronic acid analogue of isofagomine lactam as a nanomolar glucuronidase inhibitor
Lindbäck, E., Zhou, Y., López, Ó., Fernández‐Bolaños, J. G., Pedersen, C. M., & Bols, M. (2012) · Tetrahedron Letters · doi:10.1016/j.tetlet.2012.02.009 · Cited by 4
Li, Y., Wang, Z., & Cirino, P. C. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2447-6 · Cited by 4
Vomocytosis By Macrophages: A Crucial Event In The Local Niche of Tumors
Sharma, N. K., Sarode, S. C., Sarode, G. S., & Patil, S. (2019) · Future Oncology · doi:10.2217/fon-2019-0078 · Cited by 4
Biomarker discovery and beyond for diagnosis of bladder diseases
Jung, S., & Kim, J. (2020) · Bladder · doi:10.14440/bladder.2020.813 · Cited by 4
Molecular Mechanisms of Gut Microbiota-Associated Colorectal Carcinogenesis
Shao, Y., & Zeng, X. (2020) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000030 · Cited by 5
Aron‐Wisnewsky, J., Lefevre, C., & Bindels, L. B. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.01.004 · Cited by 4
Marsh, D. T., & Smid, S. D. (2022) · Food & Function · doi:10.1039/d2fo02458f · Cited by 4
Rithi, A. T., Banerjee, A., Mitra, A., Nethaji, K., Ilanchoorian, D., & Radhakrishnan, A. (2024) · Groundwater for Sustainable Development · doi:10.1016/j.gsd.2024.101187 · Cited by 6
Microbiota munch on medications, causing big effects on drug activity
Madhusoodanan, J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003785117 · Cited by 4
The role of probiotics on the roadmap to a healthy microbiota: a symposium report
Lockyer, S., Aguirre, M., Durrant, L., Pot, B., & Suzuki, K. (2020) · Gut Microbiome · doi:10.1017/gmb.2020.2 · Cited by 4
Beck, A. P., Li, H., Ervin, S. M., Redinbo, M. R., & Mani, S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/746602 · Cited by 4
Self-citationHassan, M. I., Waheed, A., Grubb, J. H., Klei, H. E., Korolev, S., & Sly, W. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138401 · Cited by 4
Chen, W., Hu, G., Dong, B.-C., Sun, H.-Y., Lu, D., Ru, M.-Y., Yu, Y., Wang, H., & Wei, B. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116596 · Cited by 4
Self-citationLiu, J., Xue, Y., Yan, H., Zhou, J., Xu, L., & Tang, Y. (2025) · Molecules · doi:10.3390/molecules30061324 · Cited by 3
Gut microbiota and chemoradiotherapy response in rectal cancer: Biomarker opportunities
Taoum, C., Devaux, A., Rouanet, P., Colombo, P., Boucher, D., & Bonnet, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104974 · Cited by 4
Supplementation and Elimination of Microbiome‐Produced Metabolites in the Treatment of Human Disease
Malogan, J., Hallowell, H. A., Francis, B., & Suez, J. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.70103 · Cited by 3
Qiu, Z., Gu, X., Gao, Q., Huang, Y., Ren, Y., He, J., Sun, X., Qu, S., Zheng, L., Xufeng, J., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157424 · Cited by 3
Tao, L., Zhao, T., Xu, Y., Chen, W., Zhu, X., Hao, Y., Zhu, L., Jiao, N., Cao, M., Pu, X., et al. (2026) · BMC Microbiology · doi:10.1186/s12866-026-04829-8 · Cited by 3
Pawłowski, P., Zaj, N., Iwaniszczuk, K., Grzelka, I., Makuch, W., Samardakiewicz-Kirol, E., Kościołek, A., & Samardakiewicz, M. (2026) · Children · doi:10.3390/children13020293 · Cited by 4
Uehara, S., Higuchi, Y., Yoneda, N., Goto, M., Yamamoto, M., Mochizuki, M., TAKAHASHI, R., Yasuda, M., Yamazaki, H., & Suemizu, H. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100269 · Cited by 3
Stepanyan, A., Kotsafti, A., Rosato, A., Castagliuolo, I., Scarpa, M., Scarpa, M., on behalf of the IMMUNOREACT Study Group, Agostini, M., Angriman, I., Antoniutti, M., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03443-9 · Cited by 3
Gut microbiome in advanced non-small cell lung cancer: effect of chemotherapy and impact on efficacy
Trachu, N., Sensorn, I., Khiewngam, K., Monnamo, N., Chantratita, W., Sirachainan, E., Reungwetwattana, T., & Oranratnachai, S. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2026-1-0209 · Cited by 3
High-throughput identification of bacterial β-glucuronidase inhibitors using machine learning
(1597939), B. Z., Yue, H., Skalse, A., Sangfuang, N., Shorthouse, D., Gaisford, S., & Basit, A. W. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2681789 · Cited by 3
Pharmacomicrobiomics mechanisms clinical applications and analytical approaches
Neelam, A. K. N., Kolli, P. K., & Atla, S. R. (2026) · Discover Pharmaceutical Sciences · doi:10.1007/s44395-026-00045-5 · Cited by 3
Microbiome and cancer: mechanistic insights, diagnostic potential, and therapeutic strategies
Kumar, V., Chaudhary, A., Gautam, M., Verma, P., & Singh, M. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1844436 · Cited by 3
Xu, K., Cui, Z., Ding, Y., Guo, T., Han, J., Yao, Y., Cai, Y., Wei, B., Bao, X., Chen, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00742 · Cited by 3
Self-citationDesign and synthesis of photoaffinity-based probes for labeling β-glucuronidase
Bi, W.-J., Lan, Z.-X., Wang, X., Cheng, Y., & Jiang, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106909 · Cited by 3
Profir, M., Roşu, O. A., Gașpar, B. S., & Creţoiu, S. M. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_305 · Cited by 4
Götz, L., Ansafi, T., Gerken, M., Klinkhammer‐Schalke, M., Fischl, A., Riemenschneider, M. J., Proescholdt, M. A., Bumes, E., Kölbl, O., Schmidt, N. O., et al. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae170 · Cited by 3
Rauf, A., Ajaj, R., Akram, Z., Khan, M., Wadood, A., Zulfat, M., Shah, Z. A., Alamri, A. S., Alsanie, W. F., Alhomrani, M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324100 · Cited by 3
Phong, N. V., Li, Y., Zhao, Y., & Yang, S. Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147487 · Cited by 3
Worms, bugs and drugs: Caenorhabditis elegans as a model for host-microbe-drug interactions
García-González, A. P., & Walhout, A. J. M. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.09.001 · Cited by 3
Characteristics of Interactions between Gut Microbiota and Degenerative Brain Diseases
Oh, S., Kim, Y.-H., & Moon, Y. I. (2016) · Current Topic in Lactic Acid Bacteria and Probiotics · doi:10.35732/ctlabp.2016.4.2.19 · Cited by 3
Influence of Antimicrobials on the Gut Microbiota
Chowdhury, G., & Ramamurthy, T. (2020) · Springer eBooks · doi:10.1007/978-981-15-3658-8_3 · Cited by 3
Noncovalently Tagged Gas Phase Complex Ions for Screening Unknown Contaminant Metabolites in Plants
Shen, M., Gong, X., Huang, S., Shen, Y., Ye, Y., Xu, J., & Ouyang, G. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03145 · Cited by 3
The interplay between anticancer challenges and the microbial communities from the gut
Hobson, C. A., Bonacorsi, S., Baruchel, A., Tenaillon, O., & Birgy, A. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04435-2 · Cited by 3
Zhu, B., Qian, C., Tang, H., Kitaguchi, T., & Ueda, H. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00165 · Cited by 3
Drugging the microbiome: targeting small microbiome molecules
Sharma, S., Hegde, P. V., Panda, S., Orimoloye, M. O., & Aldrich, C. C. (2022) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102234 · Cited by 3
Targeting Gut Microbiota in Colorectal Cancer
Wong, S. H. (2023) · Springer eBooks · doi:10.1007/978-981-19-4492-5_16 · Cited by 3
Sensors for Monitoring Faecal Indicator Bacteria in Bathing Waters
Briciu-Burghina, C., & Regan, F. B. (2023) · The handbook of environmental chemistry · doi:10.1007/698_2022_946 · Cited by 3
Development and treatment of colorectal cancer: Insights from multi‐kingdom microbiota
Hong, Y.-M., Song, D., Liu, N., & Wang, H. (2023) · Aging and Cancer · doi:10.1002/aac2.12063 · Cited by 3
Self-citationGulnaz, A., Lee, K., Kang, M.-J., Chang, J., & Chae, Y. (2024) · Toxicology Letters · doi:10.1016/j.toxlet.2024.02.011 · Cited by 3
Understanding and role of gut microbiota on drug response and toxicity
Seshadri, S., Gajjar, D., Joshi, A., Bhatia, Z., & Kumar, S. (2024) · Journal of Toxicological Studies · doi:10.59400/jts.v2i1.1252 · Cited by 4
Nelson, D. A., Veerareddy, V., Kashyap, P., Tang, X., Kalari, K. R., & Kandimalla, K. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177583 · Cited by 3
Developmental Immunotoxicology Testing (DIT)
Holsapple, M. P., Prell, R. A., & Comstock, S. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65734-3 · Cited by 3
Pan, W. D., & Kang, Y. (2017) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000120 · Cited by 3
Burchett, G. G., Folsom, C. G., & Lane, K. T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130269 · Cited by 3
Self-citationWagner, D., Özdemir, B. C., & Csajka, C. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01668 · Cited by 3
Abstracts from the 2nd International Symposium on Phytochemicals in Medicine and Food (2-ISPMF)
(2018) · Chinese Medicine · doi:10.1186/s13020-018-0172-2 · Cited by 3
Biotransformation of antioxidant eriocitrin into characteristic metabolites by the gut microbiota
Zhang, H.-J., Yu, H., Fu, J., Keranmu, A., Zhang, Z., Xu, H., Hu, J.-C., Lu, J., Yang, X., Bu, M.-M., et al. (2023) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2023.2251123 · Cited by 2
Discovering microbiota functions via chemical probe incorporation for targeted sequencing
Falco, N., & Griffin, M. E. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102551 · Cited by 2
Ali, Z., Saeed, S., Mehdi, B. J., Ahmed, H., Hussain, S. A., Bashir, N., Ashfaq, J., Muzamil, M., Zahoor, M. A., Khan, M. A., et al. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i6.1138 · Cited by 2
Safe and Efficient Intracellular Release of SN38 via Lysosomal-Responsive SN38-G Loaded Liposomes
Burnouf, P., Su, Y.-C., & Yang, S.-H. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00722 · Cited by 2
Microbiota–Drug Interaction and Its Influence on Drug Metabolism and Toxicity
Pal, R., Bhowmick, P., Mahanty, J., Halder, P., & Bhowmick, M. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-95-2104-3_3 · Cited by 3
Drug–microbiome interactions: What we know and why predictive translation remains elusive
Pereira, F. C., & Aidy, S. E. (2026) · Gut Microbes Reports · doi:10.1080/29933935.2026.2649166 · Cited by 2
Yu, L., Jiang, Y., Li, P., Wang, J., Tang, P., & Zhao, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s600863 · Cited by 2
Ahn, J. A. O. K., Hazelton, A., Nguyen, J., & Arthur, J. C. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01725-z · Cited by 2
Guo, Y.-H., Luo, L., Cheng, M.-Y., Hu, Y., Jurutka, P. W., Hu, D., Cao, C.-J., Zhang, Y., & Cheng, S. (2026) · Food & medicine homology. · doi:10.26599/fmh.2026.9420139 · Cited by 2
sedeek, M., Ayoub, A., Hany, E., Bahaa, A., Bahr, A., Saher, O., & Ahmed, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1942291 · Cited by 2
Microbiome: pharmacokinetics, pharmacodynamics and drug/xenobiotic interactions
Ojezele, M. O. (2020) · African Journal of Clinical and Experimental Microbiology · doi:10.4314/ajcem.v21i2.1 · Cited by 2
Alvarez, M. S., Billones, J. B., Lin, C., & Heralde, F. M. (2021) · Pharmacognosy Magazine · doi:10.4103/pm.pm_149_21 · Cited by 2
Immunogenic Cell Death in Cancer
Humeau, J., Naour, J. L., Kroemer, G., & Pol, J. G. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_121 · Cited by 2
Role of Microbiome in Reproductive Health: An Expanding Dimension
Pushkarna, S., Bhatnager, R., Kumar, A., Suneja, P., & Dang, A. S. (2023) · Springer eBooks · doi:10.1007/978-981-99-3126-2_16 · Cited by 3
An Insight on Gut Flora, Colorectal Cancer Mechanism, and Treatment Strategies
Kumar, R., Kaur, A., & Rajput, D. (2023) · Advanced Gut & Microbiome Research · doi:10.1155/2023/7429949 · Cited by 4
Jia, Z., Liu, X., & Liao, W. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03948-23 · Cited by 3
Coskuner, D., & Bhatt, A. P. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2024.11.004 · Cited by 2
Lee, H. J., Ji, K.-Y., Jung, D. H., Lee, J. Y., Choi, H., Kim, Y., Lee, W., Kim, T. S., Chae, S., & Hong, S. W. (2025) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2509.09045 · Cited by 2
Hashimoto, K., KINPARA, M., & Uda, Y. (2013) · Food Science and Technology Research · doi:10.3136/fstr.19.1115 · Cited by 2
Lü, B., Yang, X., Feng, X., & Li, C. (2015) · Chinese Journal of Chemical Engineering · doi:10.1016/j.cjche.2015.12.003 · Cited by 2
Repositioning of Drug – New Indications for Marketed Drugs
Kong, R., & Wong, S. T. C. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527674381.ch3 · Cited by 2
The Microbiome Revolution Turns to Cholesterol
Redinbo, M. R. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.011 · Cited by 3
Self-citationSSAT State-of-the-Art Conference: Advancements in the Microbiome
Miller, M. O., Kashyap, P., Becker, S., Thomas, R. M., Hodin, R. A., Miller, G., Barry-Hundeyin, M., Pushalkar, S., Cohen, D. J., Saxena, D. B., et al. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04551-4 · Cited by 2
Microbiota and cancer (review of literature)
Vecherkovskaya, M. F., Tetz, G. V., & Tetz, V. (2021) · The Scientific Notes of the Pavlov University · doi:10.24884/1607-4181-2020-27-4-14-27 · Cited by 2
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.